2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Various drug delivery approaches can be used to maximize therapeutic efficacy and minimize side effects, by impacting absorption, distribution, metabolism, and elimination (ADME) of a drug compound. For those drugs with poor water solubility or low permeability, techniques such as amorphous solid dispersion, liposomes, and complexations have been used to improve their oral bioavailability. Modified release (MR) formulations have been widely used to improve patient compliance, as well as to reduce side effects, especially for those drugs with short half-lives or narrow therapeutic windows. More than ten drugs using sterile long-acting release (LAR) formulations with clear clinical benefit have been successfully marketed. Furthermore, drug delivery systems have been used in delaying drug clearance processes. Additionally, modifying the in vivo drug distribution using targeted delivery systems has significantly improved oncology treatments. All the drug delivery approaches have their advantages and limitations. For both brand and generic drugs, the achievement of consistent quality and therapeutic performance using drug delivery systems can also pose serious challenges in developing a drug for the market, which requires close collaboration among industry, academia, and regulatory agencies. With the advent of personalized medicines, there will be great opportunities and challenges in utilizing drug delivery systems to provide better products and services for patients.

          Related collections

          Author and article information

          Journal
          AAPS J
          The AAPS journal
          American Association of Pharmaceutical Scientists (AAPS)
          1550-7416
          1550-7416
          Nov 2015
          : 17
          : 6
          Affiliations
          [1 ] Office of Generic Drugs, CDER, FDA, Silver Spring, Maryland, 20993, USA. hong.wen@fda.hhs.gov.
          [2 ] Office of Generic Drugs, CDER, FDA, Silver Spring, Maryland, 20993, USA.
          [3 ] Office of Pharmaceutical Quality, CDER, FDA, Silver Spring, Maryland, 20993, USA.
          Article
          10.1208/s12248-015-9814-9
          10.1208/s12248-015-9814-9
          4627459
          26276218
          deb254db-c54b-456c-a001-f750aa70a050
          History

          regulatory,targeted delivery,therapeutic performance,absorption, distribution, metabolism, and elimination (ADME),adverse effects,bioequivalence,clinical pharmacology,drug delivery,formulation design,local delivery,long-acting release,modified release,personalized medicine,pharmacokinetic profiles,prodrug,quality

          Comments

          Comment on this article